Acumen Pharmaceuticals (ABOS) Accumulated Expenses (2022 - 2026)

Acumen Pharmaceuticals' Accumulated Expenses history runs 5 years deep, the most recent figure standing at $5.3 million for Q1 2026.

• In Q1 2026, Accumulated Expenses fell 21.5% year-over-year to $5.3 million; the TTM figure through Mar 2026 stood at $5.3 million (down 21.5% YoY), while the FY2025 annual figure was $10.1 million, up 52.26% from the prior year.
• Accumulated Expenses came in at $5.3 million for Q1 2026 at Acumen Pharmaceuticals, down from $10.1 million in the prior quarter.
• In the past five years, Accumulated Expenses ranged from a high of $11.6 million in Q2 2025 to a low of $2.4 million in Q2 2023.
• A 5-year average of $5.8 million and a median of $5.3 million in 2026 frame the typical range for Accumulated Expenses.
• Across the five-year window, Accumulated Expenses surged 190.96% in 2025 and slipped 21.5% in 2026, its largest moves.
• Acumen Pharmaceuticals' Accumulated Expenses stood at $3.4 million in 2022, then soared by 92.51% to $6.4 million in 2023, then grew by 2.57% to $6.6 million in 2024, then surged by 52.26% to $10.1 million in 2025, then plunged by 47.7% to $5.3 million in 2026.
• According to Business Quant data, Accumulated Expenses over the past three periods registered $5.3 million, $10.1 million, and $7.8 million for Q1 2026, Q4 2025, and Q3 2025 respectively.

Peer Comparison